GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Institutional Ownership

BB Biotech AG (XSWX:BION) Institutional Ownership : 8.82% (As of Apr. 30, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BB Biotech AG's institutional ownership is 8.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BB Biotech AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BB Biotech AG's Float Percentage Of Total Shares Outstanding is 0.00%.


BB Biotech AG Institutional Ownership Historical Data

The historical data trend for BB Biotech AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Institutional Ownership Chart

BB Biotech AG Historical Data

The historical data trend for BB Biotech AG can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 7.84 7.85 7.77 8.53 8.48 8.55 8.84 8.94 8.78 8.82

BB Biotech AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


BB Biotech AG (XSWX:BION) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Executives
Prof. Dr. Mads Krogsgaard Thomsen Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines